Volume 1 | Issue 2 | DOI: https://doi.org/10.33696/haematology.1.007
Management of Diagnostic and Treatment Centers in the Second Wave of COVID-19
- 1MA Student in Nursing, Faculty of Nursing, Islamic Azad University of Tehran, Tehran, Iran
- 2Associate Professor of Health Services Management, Head of Innovation Center, Institute for Future Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
- 3PhD Student in Health Services Management, Faculty of Healthcare Management, Student Research Center, Kerman University of Medical Sciences, Kerman, Iran
Khalil Kalavani, email@example.com
Received Date: August 14, 2020
Accepted Date: August 24, 2020
Motie M, Dehnavieh R, Kalavani K. Toward Management of Diagnostic and Treatment Centers in the Second Wave of COVID-19. J Clin Haematol. 2020; 1(2):54-55.
Copyright: © 2020 Motie M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency.
Ketamine has long been used in the field of anesthesia . Its rapid and long-acting analgesic effects associated with its dissociative properties have also established its use in prehospital and emergency department patients.
The currently ongoing coronavirus pandemic, the SARSCOV- 2, interchangeably referred to as the COVID-19 infection, has in a short span of time altered the ways and means of almost all of mankind. So strong has been its effect that all human activity ceased in one way or another for a considerable time, led to significant loss of life and economic drain of.
Five months into the COVID-19 pandemic, the U.S. death toll from the virus has now surpassed 100,000 people. Many more cases remain nationwide, while an unknown number of patients currently harbor the virus asymptomatically. While health officials are now optimistic regarding the decline in prevalence and number of deaths due to COVID-19 and the possibility of a vaccine by the fall, we cannot lose sight of the bigger picture: the next pandemic.
Rituximab is a chimeric (20% rodent and 80% human) monoclonal antibody that binds to the CD20 antigen present on the cell surface and leads to depletion of mature B-cells [1,2]. It is the first approved monoclonal antibody to be used in the therapy of indolent B-cell non- Hodgkin’s lymphoma and chronic lymphocytic leukemia